StockData
Integra LifeSciences Holdings Corp logo

Integra LifeSciences Holdings Corp (IART) stock

IARTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 23, 2026Score 9/308% below fair value
$13.55−0.43 (-3.08%)

Close on Nov 17, 2026Market cap $1.05BP/E 79.7Yield –

Integra LifeSciences r&d expenses

Research and development expenses are spending on new products and technology.

Integra LifeSciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $94.44M, down 10.4% year over year. For fiscal 2025 it was $98.97M, down 14.2% from the year before. Over ten years it grew 6.9% a year on average. The highest annual figure on record is $115.38M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$98.97M-14.2%
FY2024Dec 31, 2024$115.38M+10.7%
FY2023Dec 31, 2023$104.19M+3.0%
FY2022Dec 31, 2022$101.19M+8.8%
FY2021Dec 31, 2021$93.05M+20.3%
FY2020Dec 31, 2020$77.38M-2.8%
FY2019Dec 31, 2019$79.57M+2.0%
FY2018Dec 31, 2018$78.04M+23.0%
FY2017Dec 31, 2017$63.46M+9.1%
FY2016Dec 31, 2016$58.16M+14.3%
FY2015Dec 31, 2015$50.90M+16.8%
FY2014Dec 31, 2014$43.56M+2.2%
FY2013Dec 31, 2013$42.62M-16.4%
FY2012Dec 31, 2012$51.01M-0.9%
FY2011Dec 31, 2011$51.45M+6.9%
FY2010Dec 31, 2010$48.11M+8.7%
FY2009Dec 31, 2009$44.28M-26.8%
FY2008Dec 31, 2008$60.50M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$21.90M-2.5%
Q2 FY2026Jun 30, 2026$24.25M-10.2%
Q1 FY2026Mar 31, 2026$23.50M-5.0%
Q4 FY2025Dec 31, 2025$24.79M-20.6%
Q3 FY2025Sep 30, 2025$22.46M-18.1%
Q2 FY2025Jun 30, 2025$27.00M-9.3%
Q1 FY2025Mar 31, 2025$24.73M-8.3%
Q4 FY2024Dec 31, 2024$31.21M+28.5%
Q3 FY2024Sep 30, 2024$27.44M+3.2%
Q2 FY2024Jun 30, 2024$29.77M+12.0%
Q1 FY2024Mar 31, 2024$26.97M+0.9%
Q4 FY2023Dec 31, 2023$24.28M-9.3%
Q3 FY2023Sep 30, 2023$26.60M+7.5%
Q2 FY2023Jun 30, 2023$26.59M+3.9%
Q1 FY2023Mar 31, 2023$26.72M+11.0%
Q4 FY2022Dec 31, 2022$26.78M+8.3%
Q3 FY2022Sep 30, 2022$24.74M-4.2%
Q2 FY2022Jun 30, 2022$25.59M+27.2%
Q1 FY2022Mar 31, 2022$24.09M+7.6%
Q4 FY2021Dec 31, 2021$24.73M+11.5%
Q3 FY2021Sep 30, 2021$25.83M+32.7%
Q2 FY2021Jun 30, 2021$20.12M+34.8%
Q1 FY2021Mar 31, 2021$22.37M+7.5%
Q4 FY2020Dec 31, 2020$22.18M-9.9%
Q3 FY2020Sep 30, 2020$19.46M+2.4%
Q2 FY2020Jun 30, 2020$14.93M-15.4%
Q1 FY2020Mar 31, 2020$20.82M+13.6%
Q4 FY2019Dec 31, 2019$24.62M+21.3%
Q3 FY2019Sep 30, 2019$19.00M-6.4%
Q2 FY2019Jun 30, 2019$17.63M-7.7%
Q1 FY2019Mar 31, 2019$18.32M-0.0%
Q4 FY2018Dec 31, 2018$20.30M+18.2%
Q3 FY2018Sep 30, 2018$20.31M+35.1%
Q2 FY2018Jun 30, 2018$19.11M+21.3%
Q1 FY2018Mar 31, 2018$18.33M+18.3%
Q4 FY2017Dec 31, 2017$17.18M+23.6%
Q3 FY2017Sep 30, 2017$15.03M–
Q2 FY2017Jun 30, 2017$15.75M–
Q1 FY2017Mar 31, 2017$15.49M–
Q4 FY2016Dec 31, 2016$13.90M–

More Integra LifeSciences figures

See a number that looks wrong?